- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases873
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases873
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PD-L1 negative
- EGFR positive
- EGFR negative
- PR positive
- ER negative
- PR negative
- ALK negative
- BRAF positive
- KRAS positive
- CD20 positive
- ALK positive
- p16 positive
- BRCA1 positive
- MET positive
- BRAF negative
- IDH positive
- BRCA2 positive
- HR positive
- HLA-A positive
- MYC positive
- ROS1 negative
- PIK3CA positive
- RET positive
- ROS1 positive
- HLA positive
- IDH negative
- TP53 positive
- p16 negative
- dMMR positive
- BCL2 positive
- BCR-ABL1 positive
- FLT3 positive
- MSI-H positive
- BCL6 positive
- BRCA positive
- HPV positive
- MET negative
- NTRK positive
- CD19 positive
- HPV negative
- RAS positive
- anti-dsDNA positive
- ANA positive
- CD123 positive
- FGFR2 positive
- HLA negative
- L858R positive
- NF1 positive
- PALB2 positive
- RET negative
- TP53 negative
- CCND1 positive
- CD5 positive
- CLDN18.2 positive
- Ex19del positive
- HBsAg positive
- HLA-A negative
- NTRK negative
- RAS negative
- BRCA1 negative
- FGFR positive
- KRAS negative
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSS positive
- NRAS positive
- PMS2 positive
- PTEN positive
- RB1 negative
- RB1 positive
- TTR positive
- ctDNA positive
- ABCA4 positive
- BRCA2 negative
- CFTR positive
- EBV positive
- KIT positive
- KMT2A positive
- MDM2 positive
- MGMT negative
- MMR positive
- NTRK1 positive
- PD-1 positive
- Philadelphia Chromosome positive
- RAF positive
- RF positive
- T790M positive
- TROP2 negative
- TROP2 positive
- anti-Sm positive
- pMMR positive
- t(11;14) positive
- APC positive
- APP positive
- ATM positive
- C5 positive
- CD22 positive
- CD23 positive
- CD30 positive
- COL7A1 positive
- FLT3 negative
- FMR1 positive
- HBV DNA negative
- HBV DNA positive
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HbSS positive
- JAK2 positive
- Ki67 positive
- MGMT positive
- MMR negative
- MSI positive
- MSI-H negative
- NF2 positive
- PD-1 negative
- PKLR positive
- PSEN1 positive
- PSEN2 positive
- RHO positive
- SMN1 positive
- SPINK5 positive
- TSC1 positive
- TSC2 positive
- anti-Ro autoantibodies positive
- dMMR negative
- β-thalassemia positive
- \-17/abn(17p) positive
- \-5/del(5q) positive
- \-7 positive
- 11q negative
- 11q positive
- AKT negative
- ALPL positive
- Anti-Smith positive
- Aβ1-42 positive
- BRCA negative
- CD20 negative
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- Complex karyotype positive
- DLL3 positive
- DMD positive
- DMPK positive
- Del(17p) negative
- ER or PR positive
- ER/PR positive
- EZH2 positive
- FAP positive
- FGFR1 positive
- FGFR3 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GATA2 positive
- GBA positive
- GLA positive
- GPC3 positive
- GRN positive
- H3K27M positive
- HBB positive
- HBcAb negative
- HBcAb positive
- HBsAg negative
- HR negative
- HRAS positive
- HbE positive
- IDS positive
- IGHV negative
- IGHV positive
- KMT2A-r positive
- L861Q positive
- LKB1 positive
- MECOM positive
- MECP2 positive
- MSI negative
- MSS negative
- MYC negative
- NPM1 positive
- NRAS negative
- PDE6A positive
- PDE6B positive
- PDGFRA positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PMM2 positive
- PTCH1 positive
- PTEN negative
- Philadelphia chromosome negative
- PiZZ positive
- RAF negative
- S768I positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- ALK TKI Therapy
- Adjuvant Radiation Therapy
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Allogeneic Hematopoietic Cell Transplantation
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
5976 trials
1
2
3
…50